Page last updated: 2024-12-05

tiaprofenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tiaprofenic acid: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tiaprofenic acid : An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5468
CHEMBL ID365795
CHEBI ID32221
SCHEMBL ID25639
MeSH IDM0075913

Synonyms (96)

Synonym
surgam sa
smr001233207
MLS002153845
BRD-A72988804-001-03-8
PRESTWICK3_000496
2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid
33005-95-7
tiaprofenic acid
PRESTWICK_814
PRESTWICK2_000496
BPBIO1_000431
alpha-methyl-5-benzoyl-2-thienylacetic acid
5-benzoyl-alpha-methylthiophene-2-acetic acid
5-benzoyl-alpha-methyl-2-thiopheneacetic acid
DB01600
2-(5-benzoyl-thiophen-2-yl)-propionic acid
D01325
ru 15060
2-(5-benzyl-2-thienyl)propionsaeure
brn 1380662
2-thiopheneacetic acid, 5-benzoyl-alpha-methyl-
acido tiaprofenico [inn-spanish]
acidum tiaprofenicum [inn-latin]
einecs 251-329-3
surgam
acide tiaprofenique [inn-french]
tiaprofensaeure
fc 3001
PRESTWICK1_000496
SPBIO_002312
PRESTWICK0_000496
BSPBIO_000391
2-(5-benzoylthiophen-2-yl)propanoic acid
acide tiaprofenique
acido tiaprofenico
acidum tiaprofenicum
CHEBI:32221 ,
ru-15060
CHEMBL365795
tiaprofenate
tiaprofen
HMS1569D13
HMS2096D13
dtxcid303665
tox21_110627
dtxsid5023665 ,
HMS2230E19
5-18-08-00405 (beilstein handbook reference)
unii-1ls1t6r34c
1ls1t6r34c ,
AKOS015969058
FT-0675220
EPITOPE ID:131796
S5661
HMS3372D06
CCG-220496
T3175
SCHEMBL25639
tox21_110627_1
NCGC00179573-03
tiaprofenic acid [ep impurity]
tiaprofenic acid [mi]
5-benzoyl-.alpha.-methyl-2-thiopheneacetic acid
tiaprofenic acid [who-dd]
tiaprofenic acid [jan]
tiaprofenic acid [inn]
tiaprofenic acid [ep monograph]
tiaprofenic acid [mart.]
alpha-(5-benzoyl-2-thienyl)propionic acid
2-thiopheneacetic acid, 5-benzoyl-.alpha.-methyl-
2-(5-benzoyl-2-thienyl)propanoic acid #
suralgan
2-(5-benzoylthiophen-2-yl)propionic acid
STL454339
2-[5-(phenylcarbonyl)thiophen-2-yl]propanoic acid
AC-8970
sr-01000841193
SR-01000841193-2
2-(5-benzoyl-2-thienyl)propanoic acid, aldrichcpr
tiaprofenic acid; (2rs)-2-(5-benzoylthiophen-2-yl)propanoic acid
J-018971
bdbm223313
mfcd00866089
HMS3713D13
Q419926
2-(5-benzoyl-2-thienyl)propanoic acid
ethyl( inverted exclamation marka)-1-[1-(4-fluorophenyl)ethyl]-1h-imidazole-4-carboxylate
2-(5-benzoylthiophen-2-yl)propanoicacid
(5-benzoyl-2-thienyl)-propionic acid
HY-106579
EX-A4101
AMY17789
CS-0026096
AS-77449
EN300-7382798
5-benzoyl-|a-methyl-2-thiopheneacetic acid

Research Excerpts

Overview

Tiaprofenic acid is a nonsteroidal anti-inflammatory drug (NSAID) Used in the treatment of patients with rheumatic diseases and other clinical conditions of pain and inflammation. orally administration of the conventional dosage forms of tiaproFenic acid invariably causes gastrointestinal side effects.

ExcerptReferenceRelevance
"Tiaprofenic acid is a widely used anti-inflammatory drug; however, the reductive metabolism of tiaprofenic acid is not yet well understood. "( Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes.
Malátková, P; Musilová, K; Skarka, A; Wsól, V, 2017
)
2.2
"Tiaprofenic acid is a propionic acid derivative with analgesic, anti-inflammatory and antipyretic properties. "( Fixed drug eruption due to tiaprofenic acid.
Bicer, A; Ikizoglu, G; Kaya, TI; Tursen, U, 2002
)
2.05
"Tiaprofenic acid is a a non-steroidal anti-inflammatory drug (NSAID). "( Single dose oral tiaprofenic acid for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moore, M; Moore, RA, 2009
)
2.14
"Tiaprofenic acid is a potent analgesic and nonsteroidal anti-inflammatory drug (NSAID) and like any other nonsteroidal anti-inflammatory drug, oral administration of the conventional dosage forms of tiaprofenic acid invariably causes gastrointestinal side effects. "( The effect of terpenes on percutaneous absorption of tiaprofenic acid gel.
Kaptan, E; Nuriyev, M; Okyar, A; Ozturk, N; Pala-Kara, Z; Yildiz, A, 2010
)
2.05
"Tiaprofenic acid is a new non-steroidal anti-inflammatory agent. "( Tiaprofenic acid in the treatment of rheumatoid arthritis.
Camp, AV, 1981
)
3.15
"Tiaprofenic acid is a photosensitizing nonsteroidal anti-inflammatory drug, whose major photoproduct (decarboxytiaprofenic acid) is also a potent photosensitizer. "( Molecular basis of drug phototoxicity: photosensitized cell damage by the major photoproduct of tiaprofenic acid.
Castell, JV; Gomez-Lechon, MJ; Hernandez, D; Martinez, LA; Miranda, MA, 1994
)
1.95
"Tiaprofenic acid is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of patients with rheumatic diseases and other clinical conditions of pain and inflammation. "( Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases.
Plosker, GL; Wagstaff, AJ, 1995
)
3.18
"Tiaprofenic acid is a chiral nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid (2-APA) class. "( Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.
Davies, NM, 1996
)
2.03
"Tiaprofenic acid is a non-steroidal anti-inflammatory drug that may cause severe non-bacterial cystitis. "( Tiaprofenic acid-induced cystitis--three cases and a literature review.
Andreassen, KH; Eldrup, J; Hansen, RI; Oster, S, 1999
)
3.19
"Tiaprofenic acid (Surgam) is a non steroidal anti-inflammatory drug used for acute inflammation during episode of upper respiratory tract infection in adults. "( [Efficacy and tolerability of tiaprofenic acid (Surgam) in acute sinusitis in adults. Results of a randomized study versus paracetamol and placebo].
Frachet, B; Genes, N; Rezvani, Y, 1991
)
2.01
"Tiaprofenic acid is a new generation anti-inflammatory drug synthesized to be a valid alternative to both cortisone preparations and other NSADs since it is less toxic yet equally effective. "( [Pharmacological and clinical profile of tiaprofenic acid].
Coppi, G, 1990
)
1.99
"Tiaprofenic acid (Surgam) is a non steroidal anti-inflammatory drug used in France for the treatment of acute inflammation, during episodes of upper respiratory tract infections of children and adults. "( [Efficacy and tolerance of tiaprofenic acid in pharyngitis in adults. Results of a randomized study vs placebo].
Benarrosh, C; Ulmann, A, 1989
)
2.02
"Tiaprofenic acid (Surgam) is a non steroidal anti-inflammatory drug used in France for the treatment of acute inflammation, during episodes of upper respiratory tract infections in children. "( [Multicenter double blind study of tiaprofenic acid versus placebo in tonsillitis and pharyngitis in children].
Benarrosh, C,
)
1.85
"Tiaprofenic acid is a non-steroidal anti-inflammatory drug which also has hypouriceamic effect. "( A study of the hypouricaemic effect of tiaprofenic acid.
Cook, JG; Fernandes, L; Lyfar, V; Thornton, E, 1988
)
1.99
"Tiaprofenic acid is a potent non-steroidal anti-inflammatory drug which, in conventional tablet form, has been shown to be rapidly absorbed and eliminated from the plasma, while synovial fluid concentrations remain constant for at least 8 hours. "( Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis.
Nichol, FE; Rose, CM; Samanta, A, 1988
)
1.95
"Tiaprofenic acid is a non-steroidal anti-inflammatory drug which is highly protein bound and excreted mainly by the kidneys. "( The pharmacokinetics of sustained release tiaprofenic acid in elderly arthritic patients.
Hosie, GA; Hosie, J, 1987
)
1.98
"Tiaprofenic acid is a new non-steroidal anti-inflammatory agent advocated for use in rheumatoid arthritis, osteoarthritis, musculoskeletal disorders, soft-tissue injuries and inflammatory conditions and acute pain of varying origin. "( Tiaprofenic acid. A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases and pain states.
Brogden, RN; Sorkin, EM, 1985
)
3.15

Effects

Tiaprofenic acid (Surgam) has been determined directly by using differential pulse polarography (DPP) and pH 5.5 acetate buffer as a supporting electrolyte. It is suggested to exhibit limited pharmacokinetic stereoselectivity.

ExcerptReferenceRelevance
"Tiaprofenic acid (Surgam) has been determined directly by using differential pulse polarography (DPP) and pH 5.5 acetate buffer as a supporting electrolyte. "( Rapid differential pulse polarographic determination of tiaprofenic acid.
Gad-Kariem, ER; Hassan, MM; Mohamed, ME; Wahbi, AA,
)
1.82
"Tiaprofenic acid has been suggested to exhibit limited pharmacokinetic stereoselectivity."( Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.
Davies, NM, 1996
)
1.31
"Tiaprofenic acid has caused at least 108 cases of cystitis and several of these patients underwent extensive urological surgery based on the assumption that they were suffering from chronic interstitial cystitis. "( Cystitis associated with tiaprofenic acid: a survey of British and Irish urologists.
Bishop, MC; Harriss, D; Henley, MJ, 1997
)
2.04

Actions

Tiaprofenic acid appeared to cause a faster onset of inhibition of PGE2 synthesis than indomethacin.

ExcerptReferenceRelevance
"Tiaprofenic acid can cause severe cystitis. "( Severe cystitis associated with tiaprofenic acid.
Crawford, ML; Waller, PC; Wood, SM, 1997
)
2.02
"Tiaprofenic acid appeared to cause a faster onset of inhibition of PGE2 synthesis than indomethacin."( Reduction of prostaglandin E2 concentrations in synovial fluid of patients suffering from rheumatoid arthritis following tiaprofenic acid or indomethacin treatment.
Daymond, TJ; Rowell, FJ, 1988
)
1.2

Treatment

Tiaprofenic acid- treated ulcers had significantly more regeneration than indomethacin-treated ulcers. Treatment with tiaproFenic acid appreciably reduced the level of plasminogen activators in the medium of 3T3-Balb mouse fibroblasts.

ExcerptReferenceRelevance
"Tiaprofenic acid-treated ulcers had significantly more regeneration than indomethacin-treated ulcers."( Tiaprofenic acid inhibits mucosal prostaglandin E2 synthesis without delaying experimental gastric ulcer healing.
Andrews, FJ; Hayles, CD; O'Brien, PE, 1998
)
2.46
"Rats treated with tiaprofenic acid for 2 weeks had ulcers of a similar size to those of controls."( Tiaprofenic acid inhibits mucosal prostaglandin E2 synthesis without delaying experimental gastric ulcer healing.
Andrews, FJ; Hayles, CD; O'Brien, PE, 1998
)
2.07
"Treatment with tiaprofenic acid appreciably reduced the level of plasminogen activators in the medium of 3T3-Balb mouse fibroblasts, as revealed by both a fibrin plate assay and amidolytic determination with chromogenic substrates. "( Plasminogen activators and tiaprofenic acid in inflammation. A preliminary study.
Caldini, R; Del Rosso, M; Fibbi, G; Magnelli, L; Pucci, M; Serni, U, 1988
)
0.92

Toxicity

ExcerptReferenceRelevance
"Cystitis, a rare adverse effect of systematically administered drugs, was first reported to be associated with a nonsteroidal antiinflammatory drug, tiaprofenic acid, in 1991."( Cystitis and nonsteroidal antiinflammatory drugs: an incidental association or an adverse effect?
Ghose, K, 1993
)
0.49
"The Medicines Adverse Reaction Monitoring Centre has been monitoring drug related events/reactions since 1965."( Cystitis and nonsteroidal antiinflammatory drugs: an incidental association or an adverse effect?
Ghose, K, 1993
)
0.29
" The photomixtures obtained in the presence of oxygen were clearly more toxic to cultured hepatocytes than those obtained under anaerobic conditions."( Involvement of drug-derived peroxides in the phototoxicity of naproxen and tiaprofenic acid.
Castell, JV; Gomez-Lechon, MJ; Grassa, C; Martinez, LA; Miranda, MA; Tarrega, P, 1993
)
0.52

Pharmacokinetics

Tiaprofenic acid has been suggested to exhibit limited pharmacokinetic stereoselectivity. Previous studies have shown no evidence of accumulation of this drug over periods of up to 12 weeks.

ExcerptReferenceRelevance
" The other pharmacokinetic parameters evaluated were not affected by headache attacks as well."( Pharmacokinetics of tiaprofenic acid after oral administration in fasting patients during and between migraine attacks.
Bergonzini, G; Bertolotti, M; Casalgrandi, L; Giroldi, L; Pini, LA; Sternieri, E, 1990
)
0.6
"The serum levels of tiaprofenic acid were determined by HPLC in 20 geriatric patients with ischemic heart disease, and the pharmacokinetic parameters were calculated."( Pharmacokinetics of tiaprofenic acid in geriatric patients with ischemic heart disease.
Eicher, H; Hilgert, D; Platt, D; Rieck, W, 1989
)
0.92
"We have studied the single dose and steady-state pharmacokinetic of tiaprofenic acid in ten elderly arthritic patients living in the community (5 men and 5 women) taking 200 mg tid for 8 days."( The pharmacokinetics of single and multiple doses of tiaprofenic acid in elderly patients with arthritis.
Hosie, GA; Hosie, J, 1987
)
0.76
" Previous pharmacokinetic studies with tiaprofenic acid in conventional formulations in elderly arthritic patients have shown no evidence of accumulation of this drug over periods of up to 12 weeks."( The pharmacokinetics of sustained release tiaprofenic acid in elderly arthritic patients.
Hosie, GA; Hosie, J, 1987
)
0.81
"To clarify the question whether pharmacokinetic properties of tiaprofenic acid (presumable trade name Surgam) can be changed by simultaneous application of aluminum hydroxide or acetylsalicylic acid (ASA) a randomized study of 7 healthy volunteers was carried out."( [On the pharmacokinetics of tiaprofenic acid and its possible interactions with acetylsalicylic acid and aluminum hydroxide (author's transl)].
Altmayer, P; Lücker, PW; Marećek, N; Penth, B; Wetzelsberger, K, 1981
)
0.8
" This finding indicates that both direct and indirect HPLC methods are suitable for pharmacokinetic study of TA enantiomers."( Pharmacokinetics of tiaprofenic acid in humans: lack of stereoselectivity in plasma using both direct and precolumn derivatization methods.
Jamali, F; Vakily, M, 1996
)
0.62
" Tiaprofenic acid has been suggested to exhibit limited pharmacokinetic stereoselectivity."( Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.
Davies, NM, 1996
)
1.5
" For powder and INC, previously reported pharmacokinetic data were used."( Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: a novel pharmacokinetic-pharmacodynamic model.
Jamali, F; Khorasheh, F; Vakily, M, 1999
)
0.55

Bioavailability

ExcerptReferenceRelevance
" A small, but significant positive deviation from linearity was observed with increasing dose for cm and AUCl-infinity in non-fasting healthy volunteers, probably due to a slightly higher bioavailability of the 300 mg formulation in the non-fasting state as compared with the 200 mg formulation."( Single dose pharmacokinetics of tiaprofenic acid. Effects of food and severe renal insufficiency.
Nilsen, OG; Walseth, F; Wessel-Aas, T, 1985
)
0.55
" The results show that the bioavailability as well as the pharmacokinetic profile of orally administered tiaprofenic acid is not changed by the mentioned compounds."( [On the pharmacokinetics of tiaprofenic acid and its possible interactions with acetylsalicylic acid and aluminum hydroxide (author's transl)].
Altmayer, P; Lücker, PW; Marećek, N; Penth, B; Wetzelsberger, K, 1981
)
0.77
" The SR formulation had a slower rate of absorption (Tmax, 4 h) and bioavailability comparable to that of the regular formulation."( Human pharmacokinetics of tiaprofenic acid after regular and sustained release formulations: lack of chiral inversion and stereoselective release.
Jamali, F; Vakily, M, 1994
)
0.59
" The bioavailability is the same as that with conventional rapid release preparations, although the peak plasma drug concentration is reduced and time peak is prolonged."( Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.
Davies, NM, 1996
)
0.59
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Tiaprofenic acid (Surgam) steady state pharmacokinetics was investigated in eight elderly patients with three different dosage regimens. The availability of a sustained release dosage form, which has a similar efficacy and tolerability profile to the standard formulation, provides a convenient once daily dosage regimen.

ExcerptRelevanceReference
" Drug studies were performed, using a 4-day dosing schedule, on optimal DTH elicited on day 10, suboptimal DTH elicited on day 15, and AA (day 16)."( Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.
Hambleton, P; McMahon, S, 1990
)
0.28
" The results of our study indicate that tiaprofenic acid at the employed dosage is suitable for the therapy of arthritis in geriatric patients suffering from ischemic heart disease, without accumulation of the drug or the development of edema."( Pharmacokinetics of tiaprofenic acid in geriatric patients with ischemic heart disease.
Eicher, H; Hilgert, D; Platt, D; Rieck, W, 1989
)
0.87
" To ensure the human therapeutic dose, each drug was given twice a day per os in 3 different dosage regimes."( Impact of NSAIDS on murine antigen induced arthritis. I. Investigation of antiinflammatory and chondroprotective effects.
de Vries, BJ; van den Berg, WB, 1989
)
0.28
" While these IC50 values might suggest different potencies for inhibition of vascular and platelet cyclooxygenases by tiaprofenic acid and, possibly, indomethacin, statistical analysis was not possible because of different slopes of the dose-response curves."( Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system.
Schrör, K; Seidel, H, 1988
)
0.48
" Tiaprofenic acid was administered orally at a dosage of 900 mg daily for 14 days and piroxicam at a dosage of 40 mg daily."( Comparative double-blind study of tiaprofenic acid versus piroxicam in the treatment of osteoarthritis of the knee.
Di Giorgio, E; Maccagno, A; Sebastian, O, 1988
)
1.46
"In a multicentre trial, tiaprofenic acid was administered in a dosage of 600 mg/day for 12 months to 109 patients with rheumatoid arthritis."( Efficacy and tolerance of tiaprofenic acid during long term administration to rheumatoid arthritis patients.
Harada, S; Konishi, Y; Nagaya, T; Niwa, S, 1988
)
0.88
" The patients received sustained action tiaprofenic acid in a dosage of 600 mg once daily for a period of 7 days."( Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis.
Nichol, FE; Rose, CM; Samanta, A, 1988
)
0.78
"An open, parallel-group study was carried out to compare the efficacy and tolerance of a sustained-release capsule formulation of tiaprofenic acid at a dosage of 600 mg once daily with standard 300 mg tiaprofenic acid tablets given twice daily."( Comparison of sustained-release with standard tiaprofenic acid in the treatment of rheumatic diseases in general practice.
Hayes, G; Phillips, G; Rose, CM; Selfridge, DI, 1987
)
0.74
" Intake of food decreased cm significantly at both dosage levels from 27."( Single dose pharmacokinetics of tiaprofenic acid. Effects of food and severe renal insufficiency.
Nilsen, OG; Walseth, F; Wessel-Aas, T, 1985
)
0.55
"Tiaprofenic acid (Surgam) steady state pharmacokinetics was investigated in eight elderly patients with three different dosage regimens: 200 mg twice daily, 400 mg twice daily and 200 mg three times daily."( Steady state pharmacokinetics of tiaprofenic acid in elderly patients.
Jacobsen, G; Nilsen, OG; Walstad, RA, 1985
)
1.99
" Using an equiefficient dosage of the active principles, referred to the ED50 in the model of adjuvant arthritis in the rat, the synthetic apparatus of the chondrocytes was stimulated by tiaprofenic acid while it was diminished by indometacin and phenylbutazone and particularly by dexamethasone."( [The effect of steroidal and nonsteroidal anti-inflammatory agents on the ultrastructure of chondrocytes in the rat. Electron microscope and morphometric study].
Annefeld, M; Cleres, C; Raiss, R, 1984
)
0.46
"To determine the effects of nabumetone, compared with tiaprofenic acid and etodolac, on anti-inflammatory efficacy and gastrointestinal irritancy in the rat when dosed orally for one month at a high anti-inflammatory dose."( Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
Blower, PR; Gentry, C; Melarange, R; Spangler, R; Toseland, CD, 1994
)
0.74
" The availability of a sustained release dosage form of tiaprofenic acid, which has a similar efficacy and tolerability profile to the standard formulation, provides a convenient once daily dosage regimen."( Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases.
Plosker, GL; Wagstaff, AJ, 1995
)
1.98
" A sustained release dosage form is available, which may be beneficial due to the short terminal phase half-life of tiaprofenic acid (3 to 6 hours)."( Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.
Davies, NM, 1996
)
0.79
" Three dosage forms were selected for this study: capsules, suppositories, and creams."( Effect of chemical structure on the release of certain propionic acid derivatives from their dosage forms.
el-Bary, AA; el-Nabarawi, MA; Mohamed, MI, 1998
)
0.3
"Tiaprofenic acid is a potent analgesic and nonsteroidal anti-inflammatory drug (NSAID) and like any other nonsteroidal anti-inflammatory drug, oral administration of the conventional dosage forms of tiaprofenic acid invariably causes gastrointestinal side effects."( The effect of terpenes on percutaneous absorption of tiaprofenic acid gel.
Kaptan, E; Nuriyev, M; Okyar, A; Ozturk, N; Pala-Kara, Z; Yildiz, A, 2010
)
2.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
thiophenesCompounds containing at least one thiophene ring.
monocarboxylic acidAn oxoacid containing a single carboxy group.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Tiaprofenic Acid Action Pathway2967

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency16.21560.007215.758889.3584AID1224835; AID588342
acetylcholinesteraseHomo sapiens (human)Potency3.89020.002541.796015,848.9004AID1347395
glp-1 receptor, partialHomo sapiens (human)Potency2.51190.01846.806014.1254AID624417
BRCA1Homo sapiens (human)Potency14.12540.89137.722525.1189AID624202
RAR-related orphan receptor gammaMus musculus (house mouse)Potency12.16930.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346859
ATAD5 protein, partialHomo sapiens (human)Potency18.34820.004110.890331.5287AID504466; AID504467
SMAD family member 3Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency19.84010.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency6.05010.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743036; AID743042; AID743053; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency26.60320.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency14.35520.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.16550.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.34800.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency15.08900.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency19.08020.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency14.96010.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.51290.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743079; AID743091
GVesicular stomatitis virusPotency15.48710.01238.964839.8107AID1645842
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency28.18380.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency7.90820.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency10.12350.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency24.65540.039147.5451146.8240AID1224845
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
histone deacetylase 9 isoform 3Homo sapiens (human)Potency7.38920.037617.082361.1927AID1259364; AID1259388
gemininHomo sapiens (human)Potency11.96460.004611.374133.4983AID624296; AID624297
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency5.95570.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency15.48710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency6.38750.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency5.95570.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase-1Homo sapiens (human)IC50 (µMol)1.09200.00201.70138.8000AID1802657
Caspase-3Homo sapiens (human)IC50 (µMol)1.09200.00021.19798.8000AID1802657
Caspase-4Homo sapiens (human)IC50 (µMol)1.09200.30002.26418.8000AID1802657
Caspase-5Homo sapiens (human)IC50 (µMol)1.09200.30002.23588.8000AID1802657
Caspase-9Homo sapiens (human)IC50 (µMol)1.09200.30002.26418.8000AID1802657
Ubiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)IC50 (µMol)2,946.00005.40006.10006.8000AID1693773
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (270)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayCaspase-3Homo sapiens (human)
luteolysisCaspase-3Homo sapiens (human)
response to hypoxiaCaspase-3Homo sapiens (human)
B cell homeostasisCaspase-3Homo sapiens (human)
negative regulation of cytokine productionCaspase-3Homo sapiens (human)
proteolysisCaspase-3Homo sapiens (human)
apoptotic processCaspase-3Homo sapiens (human)
DNA damage responseCaspase-3Homo sapiens (human)
axonal fasciculationCaspase-3Homo sapiens (human)
heart developmentCaspase-3Homo sapiens (human)
sensory perception of soundCaspase-3Homo sapiens (human)
learning or memoryCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressCaspase-3Homo sapiens (human)
response to xenobiotic stimulusCaspase-3Homo sapiens (human)
response to UVCaspase-3Homo sapiens (human)
response to woundingCaspase-3Homo sapiens (human)
response to glucoseCaspase-3Homo sapiens (human)
response to X-rayCaspase-3Homo sapiens (human)
regulation of macroautophagyCaspase-3Homo sapiens (human)
protein processingCaspase-3Homo sapiens (human)
hippocampus developmentCaspase-3Homo sapiens (human)
protein catabolic processCaspase-3Homo sapiens (human)
erythrocyte differentiationCaspase-3Homo sapiens (human)
platelet formationCaspase-3Homo sapiens (human)
negative regulation of B cell proliferationCaspase-3Homo sapiens (human)
regulation of protein stabilityCaspase-3Homo sapiens (human)
response to cobalt ionCaspase-3Homo sapiens (human)
response to estradiolCaspase-3Homo sapiens (human)
response to lipopolysaccharideCaspase-3Homo sapiens (human)
glial cell apoptotic processCaspase-3Homo sapiens (human)
response to tumor necrosis factorCaspase-3Homo sapiens (human)
response to nicotineCaspase-3Homo sapiens (human)
response to hydrogen peroxideCaspase-3Homo sapiens (human)
T cell homeostasisCaspase-3Homo sapiens (human)
response to amino acidCaspase-3Homo sapiens (human)
fibroblast apoptotic processCaspase-3Homo sapiens (human)
cell fate commitmentCaspase-3Homo sapiens (human)
negative regulation of cell cycleCaspase-3Homo sapiens (human)
negative regulation of activated T cell proliferationCaspase-3Homo sapiens (human)
striated muscle cell differentiationCaspase-3Homo sapiens (human)
response to glucocorticoidCaspase-3Homo sapiens (human)
neuron apoptotic processCaspase-3Homo sapiens (human)
protein maturationCaspase-3Homo sapiens (human)
anterior neural tube closureCaspase-3Homo sapiens (human)
pyroptosisCaspase-3Homo sapiens (human)
leukocyte apoptotic processCaspase-3Homo sapiens (human)
cellular response to staurosporineCaspase-3Homo sapiens (human)
apoptotic signaling pathwayCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-3Homo sapiens (human)
execution phase of apoptosisCaspase-3Homo sapiens (human)
positive regulation of pyroptosisCaspase-3Homo sapiens (human)
positive regulation of amyloid-beta formationCaspase-3Homo sapiens (human)
epithelial cell apoptotic processCaspase-3Homo sapiens (human)
keratinocyte differentiationCaspase-3Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-3Homo sapiens (human)
neuron differentiationCaspase-3Homo sapiens (human)
proteolysisCaspase-4Homo sapiens (human)
inflammatory responseCaspase-4Homo sapiens (human)
protein autoprocessingCaspase-4Homo sapiens (human)
defense response to bacteriumCaspase-4Homo sapiens (human)
innate immune responseCaspase-4Homo sapiens (human)
regulation of inflammatory responseCaspase-4Homo sapiens (human)
positive regulation of inflammatory responseCaspase-4Homo sapiens (human)
defense response to Gram-positive bacteriumCaspase-4Homo sapiens (human)
protein maturationCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCaspase-4Homo sapiens (human)
pyroptosisCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-4Homo sapiens (human)
non-canonical inflammasome complex assemblyCaspase-4Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-4Homo sapiens (human)
cellular response to amyloid-betaCaspase-4Homo sapiens (human)
positive regulation of interleukin-18-mediated signaling pathwayCaspase-4Homo sapiens (human)
apoptotic processCaspase-4Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-4Homo sapiens (human)
proteolysisCaspase-5Homo sapiens (human)
substantia nigra developmentCaspase-5Homo sapiens (human)
protein maturationCaspase-5Homo sapiens (human)
cellular response to mechanical stimulusCaspase-5Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-5Homo sapiens (human)
apoptotic processCaspase-5Homo sapiens (human)
positive regulation of inflammatory responseCaspase-5Homo sapiens (human)
response to hypoxiaCaspase-9Homo sapiens (human)
kidney developmentCaspase-9Homo sapiens (human)
response to ischemiaCaspase-9Homo sapiens (human)
apoptotic processCaspase-9Homo sapiens (human)
DNA damage responseCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome cCaspase-9Homo sapiens (human)
protein processingCaspase-9Homo sapiens (human)
platelet formationCaspase-9Homo sapiens (human)
response to cobalt ionCaspase-9Homo sapiens (human)
response to estradiolCaspase-9Homo sapiens (human)
response to lipopolysaccharideCaspase-9Homo sapiens (human)
glial cell apoptotic processCaspase-9Homo sapiens (human)
cellular response to UVCaspase-9Homo sapiens (human)
signal transduction in response to DNA damageCaspase-9Homo sapiens (human)
positive regulation of apoptotic processCaspase-9Homo sapiens (human)
fibroblast apoptotic processCaspase-9Homo sapiens (human)
neuron apoptotic processCaspase-9Homo sapiens (human)
protein maturationCaspase-9Homo sapiens (human)
cellular response to dexamethasone stimulusCaspase-9Homo sapiens (human)
leukocyte apoptotic processCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-9Homo sapiens (human)
epithelial cell apoptotic processCaspase-9Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
telomere maintenanceUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of DNA replicationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
DNA repairUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of DNA repairUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
DNA recombinationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
chromatin remodelingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
lateral ventricle developmentUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
midbrain developmentUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of chromosome organizationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of DNA repairUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of smoothened signaling pathwayUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of DNA-templated transcriptionUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of embryonic developmentUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
forebrain morphogenesisUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of cell cycleUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of DNA strand elongationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of proteasomal protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of telomere maintenance in response to DNA damageUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (76)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
protease bindingCaspase-3Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activityCaspase-3Homo sapiens (human)
death receptor bindingCaspase-3Homo sapiens (human)
protein bindingCaspase-3Homo sapiens (human)
peptidase activityCaspase-3Homo sapiens (human)
phospholipase A2 activator activityCaspase-3Homo sapiens (human)
protein-containing complex bindingCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-3Homo sapiens (human)
enzyme activator activityCaspase-3Homo sapiens (human)
lipopolysaccharide bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-4Homo sapiens (human)
protein bindingCaspase-4Homo sapiens (human)
lipid bindingCaspase-4Homo sapiens (human)
CARD domain bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-5Homo sapiens (human)
protein bindingCaspase-5Homo sapiens (human)
cysteine-type peptidase activityCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-9Homo sapiens (human)
protein bindingCaspase-9Homo sapiens (human)
enzyme activator activityCaspase-9Homo sapiens (human)
peptidase activityCaspase-9Homo sapiens (human)
SH3 domain bindingCaspase-9Homo sapiens (human)
protein kinase bindingCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-9Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
RNA bindingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
endopeptidase inhibitor activityUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
proteasome bindingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
cytoplasmCaspase-3Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
nucleoplasmCaspase-3Homo sapiens (human)
cytosolCaspase-3Homo sapiens (human)
neuronal cell bodyCaspase-3Homo sapiens (human)
death-inducing signaling complexCaspase-3Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
extracellular regionCaspase-4Homo sapiens (human)
mitochondrionCaspase-4Homo sapiens (human)
endoplasmic reticulumCaspase-4Homo sapiens (human)
endoplasmic reticulum membraneCaspase-4Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
plasma membraneCaspase-4Homo sapiens (human)
protein-containing complexCaspase-4Homo sapiens (human)
non-canonical inflammasome complexCaspase-4Homo sapiens (human)
cytoplasmCaspase-4Homo sapiens (human)
NLRP1 inflammasome complexCaspase-4Homo sapiens (human)
cytosolCaspase-5Homo sapiens (human)
NLRP1 inflammasome complexCaspase-5Homo sapiens (human)
cytoplasmCaspase-5Homo sapiens (human)
mitochondrionCaspase-9Homo sapiens (human)
nucleusCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
caspase complexCaspase-9Homo sapiens (human)
apoptosomeCaspase-9Homo sapiens (human)
protein-containing complexCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
cytoplasmCaspase-9Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Ino80 complexUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
nucleolusUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cytosolic proteasome complexUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID1693773Inhibition of N-terminal His6-tagged recombinant human UCHL5 expressed in Escherichia coli BL21 (DE3) codon cells assessed as reduction in cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and Rhodamine110-glycine using Ub-Rho 110 as substrate incub2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and evaluation of tiaprofenic acid-derived UCHL5 deubiquitinase inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1693772Inhibition of N-terminal His6-tagged recombinant human UCHL5 expressed in Escherichia coli BL21 (DE3) codon cells assessed as reduction in cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and Rhodamine110-glycine using Ub-Rho 110 as substrate at 202021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and evaluation of tiaprofenic acid-derived UCHL5 deubiquitinase inhibitors.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID251770Inhibition of lipopolysaccharide-induced PGE-2 production at 10e-5 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1802657Caspase Catalytic Activity Assay from Article 10.1016/j.chembiol.2017.02.003: \\Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.\\2017Cell chemical biology, Mar-16, Volume: 24, Issue:3
Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (273)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990114 (41.76)18.7374
1990's110 (40.29)18.2507
2000's24 (8.79)29.6817
2010's18 (6.59)24.3611
2020's7 (2.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.64 (24.57)
Research Supply Index5.86 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index72.42 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials58 (20.00%)5.53%
Reviews16 (5.52%)6.00%
Case Studies26 (8.97%)4.05%
Observational0 (0.00%)0.25%
Other190 (65.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect on Knee Joint Loads of Instruction in Analgesic Use Compared With NEUROMUSCULAR Exercise in Patients With Knee Osteoarthritis - A Single Blind RCT [NCT01638962]93 participants (Actual)Interventional2012-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]